Inflammation is a process whereby the immune system responds to a disease or injury. Chronic inflammation, however, has been linked to several types of cancers such as skin cancer. Molecular epidemiological studies were carried out in recent years evaluating interferon regulatory factor 4 (IRF4) rs12203592 and interleukin-6 (IL-6) gene -174G/C polymorphism associated with skin cancer risk for different groups of people. However, the results are still conflicting, not conclusive. We performed a meta-analysis to investigate the association between cancer susceptibility and IL-6 -174G/C (1130 cases and 1260 controls from 7 studies) and IRF4 rs12203592 polymorphisms (3879 cases and 6759 controls from 9 studies) in different inheritance models. We assess the strength of association of odds ratio (ORs), 95% confidence interval (CI). Overall, significantly elevated skin cancer risk was found when all studies were pooled into the meta-analysis of IL-6 -174G/C (For GC vs. GG: OR 5 1.28, 95% CI, 1.06-1.54, I 2 5 0, P heterogeneity 5 0.816; for CC/GC vs. GG: OR 5 1.26, 95% CI, 1.05-1.50, I 2 5 0, P heterogeneity 5 0.618). However, for IRF4 rs12203592 polymorphism, significantly increased risk of skin cancer was observed in TT versus CC (OR 5 1.99, 95% CI, 1.30-3.07, I 2 5 76.7%, P heterogeneity , 0.001) and in recessive model (OR 5 1.91, 95% CI, 1.31-2.77, I 2 5 69.9%, P heterogeneity , 0.001). This meta-analysis indicates that the IL-6 gene -174G/C and IRF4 rs12203592 polymorphisms may be associated with an increased skin cancer risk.
INTRODUCTION
Skin cancer is one of the most common malignancies worldwide. 1 Basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) are the most frequent types of skin cancer, and melanoma accounts for the most skin cancer deaths. The incidence of both melanoma and nonmelanoma skin cancers (NMSCs) has increased worldwide. Etiological factors associated with risk of both NMSCs as well as melanoma include skin phenotype, geographic location, and sun exposure. 2, 3 Exposure to the sun during childhood may be especially critical in the development of BCC in adult life. [4] [5] [6] Notably, it has been hypothesized that ultraviolet (UV) exposure was one of the most important environmental variables driving the evolution of human pigmentation. The risk of developing skin cancers is dependent on a combination of environmental factors and personal genetic predispositions.
Genetic variation in immune-regulating components such as cytokines may lead to interindividual differences in immunosuppression response and susceptibility
Departments of
1 Dermatology and to skin cancer. Interleukin-6 (IL-6) is a pleiotropic cytokine that has been demonstrated to regulate immune defense mechanism by initiation of acute phase of immune response. 7, 8 It is produced by many cell types in many sorts of tissues. IL-6 has been shown to act as a potent costimulator of proliferation of T cells and enhances cytotoxicity of T cells and NK cells in vitro. 9 Polymorphisms in the regulatory regions of cytokine genes have been linked to the amount of cytokine produced in vitro. [10] [11] [12] IL-6 synthesis has been related to genotypic variation sat positions 174 (G/C) in the IL-6 promoter. [10] [11] [12] The SNP rs12203592 is located in intron 4 of the interferon regulatory factor 4 (IRF4) gene, encoding a member of a helix-loop-helix family of DNAbinding transcription factors involved in downstream regulation of interferon signaling. IRFs are primarily associated with immune system development and response.
13 IRF4 is predominantly expressed not only in lymphocytes, macrophages, B-cells, and dendritic cells, but also in melanocytic lineages.
14 Involvement of this gene has been reported not only in several types of lymphoma and leukemia, 14 including childhood acute lymphoblastic leukemia, 15 but also in nonhematopoietic diseases.
14 IRF4 was initially implicated in pigmentation through the association of DNA variants located outside this gene, particularly with freckling in humans. 16 In succession, the intronic SNP rs12203592 was found to be strongly associated with hair, eye, skin color, tanning response, and nevus count. [17] [18] [19] [20] [21] This noncoding SNP was also identified to be associated with (male specific) childhood acute lymphoblastic leukemia, and, in that study, the first evidence was given that rs12203592 is located within a regulatory element, controlling expression of IRF4 through binding of transcription factor TFAP2a. 15 Recently, numerous studies have examined the potential contribution of the IL-6 gene -174G/C and IRF4 rs12203592 polymorphism to skin cancer susceptibility, but these studies have produced diverse results. [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] Given that a single study may be too underpowered to provide reliable conclusion owing to relatively small sample size, we performed this meta-analysis to estimate the association between IL-6 gene -174G/C and IRF4 rs12203592 polymorphism and skin cancer susceptibility more precisely.
MATERIALS AND METHODS

Publication search
We searched for all articles on the association between IL-6 gene -174G/C and IRF4 rs12203592 polymorphism and skin cancer susceptibility through March 2015 in the Embase and PubMed databases. The following key words were used in this search: skin cancer/basal cell carcinoma/squamous cell carcinoma, polymorphism/variant, interleukin-6/IL-6, and interferon regulatory factor 4/IRF4. Electronic retrieval was supplemented, by checking the reference lists from identified additional articles and reviews of original reports. All human-associated studies were included if they met the following criteria: (1) case-control study; (2) the outcome had to be skin cancer; (3) sufficient genotype data were presented to calculate the odds ratios (ORs) with 95% confidence intervals (CIs). The major exclusion criteria were: (1) no controls; (2) no sufficient data were reported; (3) abstract, comment, review, and editorial. Additionally, if more FIGURE 1. Flow chart of selection of studies and specific reasons for exclusion from the meta-analysis. ARMS-PCR, amplification refractory mutation system-polymerase chain reaction; CTCL, cutaneous T-cell lymphoma; HB, hospital-based; PB, population-based; PCR-RFLP, polymerase chain reaction-restriction fragment length polymorphism; PCR-SSP, polymerase chain reaction with sequence-specific primers.
than 1 article was published using the same case series, we selected the study with the largest sample size.
Data extraction
The authors independently extracted all available data from each study according to the inclusion criteria listed above. The authors resolved their differences through discussion. If this author could not reach a consensus, another author is present to negotiate to resolve the dispute, and the final decision is made by majority vote. The following data were extracted: name of the first author, year of publication, national, ethnicity, source of controls, genotyping method, the number of cases and the control group, and the distribution of genotypes of case and control groups.
Statistical analysis
Deviation of frequencies of IL-6 gene -174G/C and IRF4 rs12203592 polymorphisms from Hardy-Weinberg equilibrium (HWE) was evaluated by Chi-square test in controls, and P , 0.05 was considered as significant. The associated strength of IL-6 gene -174G/C and IRF4 rs12203592 polymorphism and the skin cancer risk was measured by ORs and 95% CI. The significance of the pooled OR is determined by the Z-test, and P , 0.05 was considered statistically significant. Subgroup analyses were performed by cancer type, source of controls, and HWE. Heterogeneity of the studies was examined by using x 2 statistic test, and P , 0.10 was considered statistically significant. When P . 0.10, the fixed-effects model (Mantel-Haenszel method) was used, otherwise a random-effects model (DerSimonian and Laird method) was used. Using Begg funnel and Egger test, the authors assessed visual symmetry in publication bias (P , 0.05, representative of statistical significance). All analyses were conducted using Stata software, version 11 (STATA Corp, College Station, TX).
RESULTS
Characteristics of the studies Figure 1 illustrates the flow chart in the form of a graph. A total of 91 articles regarding IL-6 gene -174G/C and IRF4 rs12203592 polymorphisms about skin cancer were recognized. Filtered to the title and summary, 59 articles are excluded because they are not related to skin cancer, reviews, abstracts, and repeatable results. In addition, 19 publications of these published articles were excluded because of not focusing on IL-6 -174G/C or IRF4 rs2910164 polymorphism. Another 4 publications were excluded because of no control group or the usable data were not present. A publication was incorporated through manually searching the reference lists of retrieved studies. As shown in Table 1 , meta-analysis of 16 case-control studies of 11 publications included 1130 cases and 1260 controls for IL-6 -174G/C polymorphism (7 studies from 7 publications) and 3879 cases and 6759 controls for IRF4 rs2910164 (4 studies from 9 publications). Among these studies, for IL-6 -174G/C polymorphism, there were 4 melanoma studies, 2 BCC studies, and 1 cutaneous T-cell lymphoma study. There were 5 melanoma studies, 2 BCC studies, and 2 SCC studies for or IRF4 rs2910164. The genotype distributions of all in the control group were in line with the HardyWeinberg balance except for 1 study 32 (Table 1) .
Quantitative synthesis
The assessments of the relationship of IL-6 gene -174G/C polymorphism with skin cancer risk are illustrated in Table 2 (Figure 3 ). The assessments of the relationship of IRF4 rs12203592 polymorphism with skin cancer risk are illustrated in Table 3 . Overall, significantly elevated risk of skin cancer was found in TT versus CC (OR 5 1.99, 95% CI, 1.30-3.07, I 2 5 76.7%, P heterogeneity , 0.001) and in recessive model (OR 5 1.91, 95% CI, 1.31-2.77, I 2 5 69.9%, P heterogeneity , 0.001) (Figure 4 ) when all eligible studies were summarized in meta-analysis. There was significant heterogeneity among these studies. 
Publication bias
Publication bias was assessed by Begg and Egger regression tests. No statistical significance of publication bias was found by Egger test to IL-6 -174G/C polymorphism in dominant model (P 5 0.605) ( Figure 5A ). However, the P value of Egger test verified the existence of publication bias with regard to the IRF4 rs12203592 polymorphism and skin cancer in recessive model (P 5 0.013) ( Figure 5B ).
DISCUSSION
Cancer is an environmental disease, and skin cancer (melanoma and nonmelanoma) is the most common of all cancers. There are 4 different types of skin cancer: BCC and SCC collectively referred to as NMSCs or keratinocyte carcinoma, melanoma, and other nonepithelial skin cancer. BCC and SCC account for approximately 80% and 16% of all NMSCs, respectively. hallmarks in solar UV radiation and several other environmental agent-mediated skin cancers. 33 Human gene polymorphism has been shown indeed to play a role in immune responses. Some polymorphisms of immune-related genes may have direct functional significance by altering directly and indirectly the level of gene expression and/or its function. The IL-6 -174G/C and IRF4 rs12203592 polymorphisms had been implicated in skin cancer susceptibility. More and more studies have investigated the relationship of IL-6 -174G/C and IRF4 rs12203592 polymorphisms with skin cancer risk [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] ; however, the results are contradictory. To get a comprehensive conclusion, we searched the literature from PubMed and EMBASE databases and conducted meta-analysis. In this metaanalysis, a total of 16 studies were included. Among them, there were 7 studies with 1130 cases and 1260 controls for IL-6 -174G/C and 9 studies with 3879 cases and 6759 controls for IRF4 rs12203592. Overall, significantly elevated risk of skin cancer was found when all eligible studies were summarized in a metaanalysis of IL-6 -174G/C (for GC vs. GG: OR 5 1.28, 95% CI, 1.06-1.54, I 2 5 0, P heterogeneity 5 0.816; for CC/ GC vs. GG: OR 5 1.26, 95% CI, 1.05-1.50, I 2 5 0, P heterogeneity 5 0.618). However, for IRF4 rs12203592 polymorphism, significantly elevated risk of skin cancer was found in TT versus CC (OR 5 1.99, 95% CI, 1.30-3.07, I 2 5 76.7%, P heterogeneity , 0.001) and in recessive model (OR 5 1.91, 95% CI, 1.31-2.77, I 2 5 69.9%, P heterogeneity , 0.001). This meta-analysis demonstrates that the IL-6 gene -174G/C and IRF4 rs12203592 polymorphisms may be associated with an elevated skin cancer risk.
The levels of pro-and anti-inflammatory cytokines would be expected to play an important role in the initial stages of tumorigenesis and could thus contribute to the risk for the disease. Cytokines, such as IL-6, TGF b1, and IL-4, can influence growth of transformed cells [34] [35] [36] besides being potent immunomodulators. [37] [38] [39] The IRF4 gene product is a member of the IRF family of transcription factors, 40 which are involved in the regulation of gene expression in response to interferon and other cytokines. The IRF4 gene encodes a B-cell proliferation/differentiation protein that has been proposed as a sensitive and specific marker for conventional primary and metastatic melanomas and benign melanocytic nevi. 41 In addition to pigmentation, IRF4 may also have an effect on skin cancer risk through its role in immune response. Through its effects on B-cell lineage and consequently on the cellular immune response, IRF4 polymorphisms may have a pathophysiologic role via limiting the host immune response against atypical melanocytes and keratinocytes in the skin.
Although we made every effort to control the statistical estimates of potential bias and estimated the association between IL-6 -174G/C and IRF4 rs12203592 polymorphisms and skin cancer as reliable as possible, some of the limitations of this study deserve attention. First, the meta-analysis on the basis of summary data, rather than to individual participant data, is unable to further elucidate the interaction between genes and the environment. Second, although comprehensive literature searching PubMed and EMBASE databases were no language restrictions, the P value of Egger test indicated the existence of publication bias for IRF4 rs12203592 polymorphism in association with skin cancer. Third, including eligible research, not a large enough sample size, limited statistical power to a certain extent. More studies with larger sample size are needed in the future to better explain our results.
Overall, despite these limitations, the meta-analysis showed that the IL-6 gene -174G/C and IRF4 rs12203592 polymorphisms may be associated with the elevated risk of skin cancer. Large and welldesigned studies are needed to further verify this relationship in the future.
